Tim Davis appointed as new Chief Executive Officer and Jeremy Edwards named the new Chief Commercial Officer
Ottignies, BELGIUM – International Drug Development Institute (IDDI), a privately held, expert regulatory statistics and clinical data science service provider in the field of clinical research based in Belgium, with offices in Raleigh, NC, USA, has announced significant changes to its executive leadership team.
KEY APPOINTMENTS
Tim Davis has been named the new Chief Executive Officer and brings over 25 years of experience in the pharmaceutical, life sciences, and digital health sectors. He has led strategic initiatives at Veeva Systems, including the launch of MyVeeva for Patients and Veeva’s eConsent and eCOA solutions. With a track record in scaling operations, fundraising, and business development, Tim co-founded patient engagement and data capture pioneers – Exco InTouch Ltd, which was subsequently acquired by ERT. He has held leadership roles in digital patient engagement and eClinical, with a strong focus on patient experience and innovative solutions.
Additionally, Jeremy Edwards has been named the new Chief Commercial Officer at IDDI. With 27 years of experience across the clinical development continuum, Jeremy has held executive leadership roles in both full-service CROs and specialized eClinical service providers. He is highly skilled in expanding European-based organizations into the US market, creating new business verticals, scaling operations, and driving revenue growth. Notably, Jeremy previously worked alongside Tim Davis in the successful growth of Exco InTouch, showcasing his ability to foster innovation and improve commercial performance.
STRATEGIC IMPACT
The appointment of Davis and Edwards is expected to significantly strengthen IDDI’s leadership and operational capabilities. Dr. Marc Buyse, IDDI’s founder and Chief Scientific Officer, expressed confidence in the new leadership team, stating:
“Tim’s wealth of managerial and operational expertise combined with Jeremy’s commercial and marketing experience will broaden our strategic leadership and operational excellence at IDDI. Their proven track record of working together will play a key role in strengthening our patient-centric solutions. By collaborating with our sister company, One2Treat, we intend to further innovate these solutions, focusing on integrating key patient-relevant outcomes to enhance treatment decisions and market access evaluations.”
FUTURE OUTLOOK
With the new leadership team in place, IDDI is well-positioned for future expansion and improved value delivery to its customers, employees, and the life sciences sector. By collaborating with its sister company, One2Treat, IDDI intends to further innovate its patient-centric solutions, addressing all phases from trial design to regulatory approval for clients throughout the USA and Europe, focusing on integrating key patient-relevant outcomes to enhance treatment decisions and market access evaluations.
“I am thrilled to take on the role of CEO at IDDI and collaborate with such a skilled team. I am eager to apply my experience in digital health and clinical trials to foster innovation and improve the patient experience. Together, we will build on IDDI’s solid foundation and work towards even greater achievements in advancing clinical research,” stated Tim Davis.
ABOUT IDDI:
Founded in 1991, IDDI is a leader in regulatory statistics and clinical data science, offering agile clinical trial services and efficient strategies for FDA and EMA submissions. We support pharmaceutical, biotech, and medical device/diagnostic companies across various disease areas, including oncology, ophthalmology, CNS, and rare diseases. Headquartered in Brussels, Belgium, IDDI also operates in the United States from Raleigh, North Carolina.
Contact: [email protected]